These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 27435344

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. N-substituted piperazinopyridylsteroid derivatives as abiraterone analogues inhibit growth and induce pro-apoptosis in human hormone-independent prostate cancer cell lines.
    Brossard D, Zhang Y, Haider SM, Sgobba M, Khalid M, Legay R, Duterque-Coquillaud M, Galera P, Rault S, Dallemagne P, Moslemi S, El Kihel L.
    Chem Biol Drug Des; 2013 Nov; 82(5):620-9. PubMed ID: 23906044
    [Abstract] [Full Text] [Related]

  • 6. Illuminating cytochrome P450 binding: Ru(ii)-caged inhibitors of CYP17A1.
    Li A, Yadav R, White JK, Herroon MK, Callahan BP, Podgorski I, Turro C, Scott EE, Kodanko JJ.
    Chem Commun (Camb); 2017 Mar 28; 53(26):3673-3676. PubMed ID: 28304025
    [Abstract] [Full Text] [Related]

  • 7. Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
    Udhane SS, Dick B, Hu Q, Hartmann RW, Pandey AV.
    Biochem Biophys Res Commun; 2016 Sep 02; 477(4):1005-1010. PubMed ID: 27395338
    [Abstract] [Full Text] [Related]

  • 8. Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
    Bonomo S, Hansen CH, Petrunak EM, Scott EE, Styrishave B, Jørgensen FS, Olsen L.
    Sci Rep; 2016 Jul 12; 6():29468. PubMed ID: 27406023
    [Abstract] [Full Text] [Related]

  • 9. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.
    Cheong EJY, Nair PC, Neo RWY, Tu HT, Lin F, Chiong E, Esuvaranathan K, Fan H, Szmulewitz RZ, Peer CJ, Figg WD, Chai CLL, Miners JO, Chan ECY.
    J Pharmacol Exp Ther; 2020 Sep 12; 374(3):438-451. PubMed ID: 32554434
    [Abstract] [Full Text] [Related]

  • 10. CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β,6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone.
    de Mello Martins AGG, Allegretta G, Unteregger G, Haupenthal J, Eberhard J, Hoffmann M, van der Zee JA, Junker K, Stöckle M, Müller R, Hartmann RW, Ohlmann CH.
    J Steroid Biochem Mol Biol; 2017 Nov 12; 174():183-191. PubMed ID: 28890368
    [Abstract] [Full Text] [Related]

  • 11. Dirty deeds done dirt cheap: sensitization of prostate cancer cells to abiraterone treatment using hydroxylated polychlorinated biphenyls.
    Daragan G, Hoffmann J, Vasko T, Mustea A, Burchardt M, Kraus T, Stope MB, Ziegler P.
    Invest New Drugs; 2020 Apr 12; 38(2):541-545. PubMed ID: 31292837
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and Biological Evaluation of Methoxypolyethylene-Glycol-Substituted Abiraterone Derivatives as Potential Antiprostate Cancer Agents.
    Meng S, Zhu N, Han D, Li B, Zhang X, Zhang J, Liu T.
    Mol Pharm; 2024 Jul 01; 21(7):3186-3203. PubMed ID: 38815167
    [Abstract] [Full Text] [Related]

  • 13. Comparative study of the binding mode between cytochrome P450 17A1 and prostate cancer drugs in the absence of haem iron.
    Song D, Zhang J, Wang Y, Hu J, Xu S, Xu Y, Shen H, Wen X, Sun Z.
    J Biomol Struct Dyn; 2019 Oct 01; 37(16):4161-4170. PubMed ID: 30431391
    [Abstract] [Full Text] [Related]

  • 14. [CYP17A1 inhibitors in prostate cancer: mechanisms of action independent of the androgenic pathway].
    Audenet F, Murez T, Ripert T, Villers A, Neuzillet Y.
    Prog Urol; 2013 Oct 01; 23 Suppl 1():S9-15. PubMed ID: 24314739
    [Abstract] [Full Text] [Related]

  • 15. Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site.
    Petrunak EM, Bart AG, Peng HM, Auchus RJ, Scott EE.
    J Biol Chem; 2023 Mar 01; 299(3):102999. PubMed ID: 36773804
    [Abstract] [Full Text] [Related]

  • 16. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
    Turitto G, Di Bisceglie M, Moraca L, Sasso N, Sepede C, Suriano A, Romito S.
    Recenti Prog Med; 2012 Feb 01; 103(2):74-8. PubMed ID: 22430753
    [Abstract] [Full Text] [Related]

  • 17. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
    Bird IM, Abbott DH.
    J Steroid Biochem Mol Biol; 2016 Oct 01; 163():136-46. PubMed ID: 27154414
    [Abstract] [Full Text] [Related]

  • 18. Interaction of 17α-hydroxylase, 17(20)-lyase (CYP17A1) inhibitors - abiraterone and galeterone - with human sterol 14α-demethylase (CYP51A1).
    Masamrekh R, Kuzikov A, Veselovsky A, Toropygin I, Shkel T, Strushkevich N, Gilep A, Usanov S, Archakov A, Shumyantseva V.
    J Inorg Biochem; 2018 Sep 01; 186():24-33. PubMed ID: 29807244
    [Abstract] [Full Text] [Related]

  • 19. Discovery of Novel Non-Steroidal Cytochrome P450 17A1 Inhibitors as Potential Prostate Cancer Agents.
    Wróbel TM, Rogova O, Andersen KL, Yadav R, Brixius-Anderko S, Scott EE, Olsen L, Jørgensen FS, Björkling F.
    Int J Mol Sci; 2020 Jul 09; 21(14):. PubMed ID: 32660148
    [Abstract] [Full Text] [Related]

  • 20. Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2.
    Fehl C, Vogt CD, Yadav R, Li K, Scott EE, Aubé J.
    J Med Chem; 2018 Jun 14; 61(11):4946-4960. PubMed ID: 29792703
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.